Changes in Choroidal Thickness after Panretinal Photocoagulation in Diabetic Retinopathy Patients

Sung Yu; Yong Il Kim; Kyoo Won Lee; Hyun Gu Kang

doi:10.3341/jkos.2016.57.2.256

Journal List > J Korean Ophthalmol Soc > v.57(2) > 1010505

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Yu, Kim, Lee, and Kang: Changes in Choroidal Thickness after Panretinal Photocoagulation in Diabetic Retinopathy Patients

Original Article

J Korean Ophthalmol Soc 2016;57(2):256-263.

Published online: 7 September 2016

DOI: https://doi.org/10.3341/jkos.2016.57.2.256

Changes in Choroidal Thickness after Panretinal Photocoagulation in Diabetic Retinopathy Patients

Sung Yu, MD, Yong Il Kim, MD, Kyoo Won Lee, MD, PhD, Hyun Gu Kang, MD

Cheil Eye Hospital, Daegu, Korea

Address reprint requests to Hyun Gu Kang, MD Cheil Eye Hospital, #1 Ayang-ro, Dong-gu, Daegu 41196, Korea Tel: 82-53-959-1751, Fax: 82-53-959-1758 E-mail: flowerchild03@hanmail.net

Received 12 June 2015 Revised 31 October 2015 Accepted 30 December 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

To investigate the changes in choroidal thickness in diabetic retinopathy patients after panretinal photocoagulation (PRP).

Methods

This retrospective study included 42 eyes of treatment-naïve, severe non-proliferative diabetic retinopathy or proliferative diabetic retinopathy patients undergoing 3-session PRP. At baseline and 1 and 2 months after completion of the PRP treatments, subfoveal choroidal thickness (SFCT) was measured using enhanced depth imaging optical coherence tomography.

Results

The mean SFCT at baseline was 261.52 ± 77.98 µm, changing to 249.14 ± 72.23 μm and 242.95 ± 70.28 μm at 1 and 2 months, respectively (p < 0.05). The mean central macular thickness (CMT) was increased (>10%) in 9 eyes (21.43%) at 1 month and 8 eyes (19.05%) at 2 months after PRP. The mean SFCT showed no significant difference between increased mean CMT (238.22 ± 57.59 μm and 240.00 ± 67.71 μm at 1 and 2 months, respectively) and stable mean CMT groups (252.12 ± 76.24 μm and 243.65 ± 71.84 μm at 1 and 2 months, respectively; p > 0.05).

Conclusions

Choroidal thickness decreased after PRP. There was no significant relationship between change in SFCT and CMT after PRP.

Keywords: Choroidal thickness, Diabetic retinopathy, Enhanced depth imaging optical coherence tomography, Panretinal photocoagulation

REFERENCES

1). Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991; 98:(5 Suppl). 766–85.

2). Ferris F. Early photocoagulation in patients with either type I or type II diabetes. Trans Am Ophthalmol Soc. 1996; 94:505–37.

3). Bressler NM, Beck RW, Ferris FL 3rd.Panretinal photocoagulation for proliferative diabetic retinopathy. N Engl J Med. 2011; 365:1520–6.

4). Blondeau P, Pavan PR, Phelps CD. Acute pressure elevation following panretinal photocoagulation. Arch Ophthalmol. 1981; 99:1239–41.

5). Lerner BC, Lakhanpal V, Schocket SS. Transient myopia and accommodative paresis following retinal cryotherapy and panretinal photocoagulation. Am J Ophthalmol. 1984; 97:704–8.

6). Pahor D. Visual field loss after argon laser panretinal photocoagulation in diabetic retinopathy: full- versus mild-scatter coagulation. Int Ophthalmol. 1998; 22:313–9.

7). Yuki T, Kimura Y, Nanbu S, et al. Ciliary body and choroidal detachment after laser photocoagulation for diabetic retinopathy. A high-frequency ultrasound study. Ophthalmology. 1997; 104:1259–64.

8). Ryan SJ. Retina. 4th ed.Vol. 1. Philadelphia: Elsevier Mosby;2006. p. 33.

9). Spaide RF, Koizumi H, Pozzoni MC. Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol. 2008; 146:496–500.

10). Querques G, Lattanzio R, Querques L, et al. Enhanced depth imaging optical coherence tomography in type 2 diabetes. Invest Ophthalmol Vis Sci. 2012; 53:6017–24.

11). Cho JH, Bae SH, Han JR, et al. Comparison of choroidal thickness in eyes with central serous chorioretinopathy, asymptomatic fellow eyes and normal eyes. J Korean Ophthalmol Soc. 2012; 53:87–93.

12). Kim KH, Kim DG. The relationship among refractive power, axial length and choroidal thickness measured by SD-OCT in myopia. J Korean Ophthalmol Soc. 2012; 53:626–31.

13). Lee SH, Chung HW, Kim HC. Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy. J Korean Ophthalmol Soc. 2012; 53:982–7.

14). Kim JW, Kim YT. Changes in subfoveal choroidal thickness in malignant hypertension patients. J Korean Ophthalmol Soc. 2014; 55:840–6.

15). Park JS, Cho YW, Jang JH. Choroid in myopic choroidal neo-vascularization measured using SD-OCT. J Korean Ophthalmol Soc. 2014; 55:1313–9.

16). Kim JH, Kim JS, Lee KW, Lee JH. The posterior choroidal profiles measured by spectral domain optical coherence tomography in healthy Korean children. J Korean Ophthalmol Soc. 2013; 54:1708–14.

17). Park BJ, Chung HW, Kim HC. Effects of diabetic retinopathy and intravitreal bevacizumab injection on choroidal thickness in diabetic patients. J Korean Ophthalmol Soc. 2013; 54:1520–5.

18). Cho GE, Cho HY, Kim YT. Change in subfoveal choroidal thickness after argon laser panretinal photocoagulation. Int J Ophthalmol. 2013; 6:505–9.

19). Margolis R, Spaide RF. A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. Am J Ophthalmol. 2009; 147:811–5.

20). Ikuno Y, Kawaguchi K, Nouchi T, Yasuno Y. Choroidal thickness in healthy Japanese subjects. Invest Ophthalmol Vis Sci. 2010; 51:2173–6.

21). Agawa T, Miura M, Ikuno Y, et al. Choroidal thickness measurement in healthy Japanese subjects by three-dimensional high-penetration optical coherence tomography. Graefes Arch Clin Exp Ophthalmol. 2011; 249:1485–92.

22). Tan CS, Ouyang Y, Ruiz H, Sadda SR. Diurnal variation of choroidal thickness in normal, healthy subjects measured by spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2012; 53:261–6.

23). Lee SW, Yu SY, Seo KH, et al. Diurnal variation in choroidal thickness in relation to sex, axial length, and baseline choroidal thickness in healthy Korean subjects. Retina. 2014; 34:385–93.

24). Hidayat AA, Fine BS. Diabetic choroidopathy. Light and electron microscopic observations of seven cases. Ophthalmology. 1985; 92:512–22.

25). Fryczkowski AW, Hodes BL, Walker J. Diabetic choroidal and iris vasculature scanning electron microscopy findings. Int Ophthalmol. 1989; 13:269–79.

26). Regatieri CV, Branchini L, Carmody J, et al. Choroidal thickness in patients with diabetic retinopathy analyzed by spectral-domain optical coherence tomography. Retina. 2012; 32:563–8.

27). Kim JT, Lee DH, Joe SG, et al. Changes in choroidal thickness in relation to the severity of retinopathy and macular edema in type 2 diabetic patients. Invest Ophthalmol Vis Sci. 2013; 54:3378–84.

28). Zhu Y, Zhang T, Wang K, et al. Changes in choroidal thickness after panretinal photocoagulation in patients with type 2 diabetes. Retina. 2015; 35:695–703.

29). Zhang Z, Meng X, Wu Z, et al. Changes in choroidal thickness after panretinal photocoagulation for diabetic retinopathy: a 12-week longitudinal study. Invest Ophthalmol Vis Sci. 2015; 56:2631–8.

30). Shimura M, Yasuda K, Nakazawa T, et al. Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision. Ophthalmology. 2003; 110:2386–94.

31). Lee SB, Yun YJ, Kim SH, Kim JY. Changes in macular thickness after panretinal photocoagulation in patients with severe diabetic retinopathy and no macular edema. Retina. 2010; 30:756–60.

32). Nagaoka T, Kitaya N, Sugawara R, et al. Alteration of choroidal circulation in the foveal region in patients with type 2 diabetes. Br J Ophthalmol. 2004; 88:1060–3.

33). Takahashi A, Nagaoka T, Sato E, Yoshida A. Effect of panretinal photocoagulation on choroidal circulation in the foveal region in patients with severe diabetic retinopathy. Br J Ophthalmol. 2008; 92:1369–73.

34). Oh IK, Kim SW, Oh J, et al. Inflammatory and angiogenic factors in the aqueous humor and the relationship to diabetic retinopathy. Curr Eye Res. 2010; 35:1116–27.

35). Berkowitz BA, Sato Y, Wilson CA, Juan E. Blood-retinal barrier breakdown investigated by real-time magnetic resonance imaging after gadolinium-diethylenetriaminepentaacetic acid injection. Invest Ophthalmol Vis Sci. 1991; 32:2854–60.

36). Kim JH, Yu S, Kim JS, et al. Difference in subfoveal choroidal thickness between two spectral-domain optical coherence tomography systems. J Korean Ophthalmol Soc. 2014; 55:1327–33.

37). Lee KH, Lee SC, Lee CS. Reproducibility of choroidal thickness in normal Korean eyes using two spectral domain optical coherence tomography. J Korean Ophthalmol Soc. 2013; 54:1365–70.

Figure 1.

Changes in BCVA, IOP, MCT, SFCT after PRP. (A) BCVA did not changed significantly 1 and 2 months after PRP compared with baseline(p > 0.05). (B) IOP did not changed significantly 1 and 2 months after PRP compared with baseline(p > 0.05). (C) MCT increased significantly 1 and 2 months after PRP compared with baseline(p < 0.05). (D) SFCT decreased significantly 1 and 2 months after PRP compared with baseline (p < 0.05). Compared with pre-treatment by repeated measure ANOVA. BCVA =best corrected visual acuity; IOP = intraocular pressure; MCT = macular center thickness; SFCT = subfoveal choroidal thickness; PRP = panretinal photocoagulation; ANOVA = analysis of variance. ^* p < 0.05.

Figure 2.

Comparison of SFCT in ME group and non-ME group. (A) At 1 month, there was no significant difference between two groups (p > 0.05). (B) At 2 months, there was no significant difference between two groups (p > 0.05). Macular edema group means the patients that macular center thickness was increased more than 10% after panretinal photocoagulation. Compared by Mann-Whitney U-test. SFCT = subfoveal choroidal thickness; ME = macular edema.

Figure 3.

Scatter plots for correlation between change in MCT and SFCT. (A) At 1 month, there was no significant correlation between change in MCT and SFCT (r = 0.009, p = 0.957). (B) At 2 month, there was no significant correlation between change in MCT and SFCT (r = 0.201, p = 0.201). Compared by Pearson's correlation analysis. r = coefficient of correlation; MCT = macular center thickness; SFCT = subfoveal choroidal thickness.

Figure 4.

Comparison of MCT and SFCT between severe-NPDR and PDR. (A) There was no significant difference in MCT between two groups at baseline, 1 month and 2 months after PRP (p > 0.05). (B) There was no significant difference in SFCT between two groups at baseline, 1 month and 2 months after PRP (p > 0.05). Compared by Mann-Whitney U-test. MCT = macular center thickness; SFCT = subfoveal choroidal thickness; NPDR = non-proliferative diabetic retinopathy; PDR = proliferative diabetic retinopathy; PRP = panretinal photocoagulation.

Table 1.

Demographics of patients

Parameters	Values
Number of eyes	42
Laterality (OD:OS)	23:19
Sex (male:female)	29:13
Age (years)	60.40 ± 10.01
SE (diopter)	0.25 ± 1.38
Visual acuity (log MAR)	0.25 ± 0.17
IOP (mm Hg)	13.79 ± 3.04
MCT (μ m)	272.10 ± 18.12
SFCT (μ m)	261.52 ± 77.98

Values are presented mean ± standard deviation.

SE = spherical equivalent; IOP = intraocular pressure; MCT = macular center thickness; SFCT = subfoveal choroidal thickness.

TOOLS

Similar articles